Articles

In patients with platinum-sensitive recurrent epithelial ovarian cancer, olaparib monotherapy did not improve survival over standard-of-care chemotherapy. Read More ›

After discontinuing treatment with a PARP inhibitor, waiting longer to initiate subsequent therapy was associated with better tolerance to post–PARP inhibitor therapy, with no negative impact on progression-free survival. Read More ›

Patient-reported outcomes from nearly 2000 women with gynecologic cancers revealed that black women have more suffering, less support, and worse health than white women. Read More ›

Progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy overall and across all important subgroups. Read More ›

Initial findings from a large-scale, patient-reported outcomes program reveal that patients with gynecologic malignancy do not report worse quality of life after surgery. Read More ›

New research shows that treatment with niraparib does not negatively impact quality of life in patients with ovarian cancer. Read More ›

In an exploratory analysis of a phase 3 study, niraparib improved progression-free survival in patients with advanced ovarian cancer across all important subgroups. Read More ›

Preliminary data on time to first subsequent therapy and second progression-free survival support clinical benefit of niraparib over placebo. Read More ›

Zanubrutinib (Brukinsa), a novel Bruton tyrosine kinase (BTK) inhibitor—which was approved by the FDA in November 2019 for the treatment of mantle-cell lymphoma—achieved high overall response rate (ORR) and durable responses in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including those with high-risk cytogenetics, according to findings presented at ASH 2019.

Read More ›

Almost 50% of patients with chronic lymphocytic leukemia (CLL) who received treatment with the triplet of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva) as first-line therapy achieved undetectable minimal residual disease (MRD) in the bone marrow after only 8 monthly cycles of therapy, according to data presented at ASH 2019.

Read More ›